• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

    17.69 -0.79 (-4.27%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 29, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 913,785
    Open 18.05
    Bid (Size) 17.58 (100)
    Ask (Size) 17.66 (100)
    Prev. Close 18.48
    Today's Range 17.60 - 18.05
    52wk Range 15.96 - 44.34
    Shares Outstanding 956,637,360
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Zai Lab Announces Changes to Senior Leadership Team
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗
    Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model. 
    Via The Motley Fool
    Topics Intellectual Property Regulatory Compliance

    Performance

    YTD
    +2.1%
    +2.1%
    1 Month
    -14.7%
    -14.7%
    3 Month
    -8.0%
    -8.0%
    6 Month
    -13.3%
    -13.3%
    1 Year
    -43.5%
    -43.5%

    More News

    Read More
    News headline image
    Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year ↗
    Via The Motley Fool
    Topics Economy Regulatory Compliance
    News headline image
    Earnings Scheduled For November 6, 2025 ↗
    Via Benzinga
    News headline image
    Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab Announces Updates to China’s National Reimbursement Drug List
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Nuvation Bio (NUVB) Soars on IBTROZI's Blockbuster Launch and Stellar Q3 2025 Performance
    Via MarketMinute
    News headline image
    Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab Announces Participation in Investor Conferences in November and December 2025
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study
    From Zai Lab Limited
    Via Business Wire
    News headline image
    Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025
    From Zai Lab Limited
    Via Business Wire

    Frequently Asked Questions

    Is Zai Lab Limited - American Depositary Shares publicly traded?
    Yes, Zai Lab Limited - American Depositary Shares is publicly traded.
    What exchange does Zai Lab Limited - American Depositary Shares trade on?
    Zai Lab Limited - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Zai Lab Limited - American Depositary Shares?
    The ticker symbol for Zai Lab Limited - American Depositary Shares is ZLAB on the Nasdaq Stock Market
    What is the current price of Zai Lab Limited - American Depositary Shares?
    The current price of Zai Lab Limited - American Depositary Shares is 17.69
    When was Zai Lab Limited - American Depositary Shares last traded?
    The last trade of Zai Lab Limited - American Depositary Shares was at 05/29/26 04:00 PM ET
    What is the market capitalization of Zai Lab Limited - American Depositary Shares?
    The market capitalization of Zai Lab Limited - American Depositary Shares is 16.92B
    How many shares of Zai Lab Limited - American Depositary Shares are outstanding?
    Zai Lab Limited - American Depositary Shares has 17B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.